Intelligence · INN Directory
Pharmaceutical Drugs
Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.
- Drugs indexed
- 3,385
- Companies
- 1,062
- Pipeline programs
- 18,156
Quick answer
NovaPharmaNews tracks 3,385 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.
-
amivantamab and hyaluronidase-lpuj
RYBREVANT FASPRO
-
atezolizumab and hyaluronidase-tqjs
TECENTRIQ HYBREZA
-
daratumumab and hyaluronidase-fihj
DARZALEX FASPRO
-
efgartigimod alfa and hyaluronidase-qvfc
VYVGART HYTRULO
-
hyaluronidase
VITRAGAN Amphastar France Pharmaceuticals
-
hyaluronidase recombinant human
HYLENEX RECOMBINANT HALOZYME THERAPEUTICS, INC.
-
ocrelizumab and hyaluronidase-ocsq
OCREVUS ZUNOVO
-
pertuzumab, trastuzumab, and hyaluronidase-zzxf
PHESGO
-
trastuzumab and hyaluronidase-oysk
HERCEPTIN HYLECTA
Frequently asked questions
What is the NovaPharmaNews drugs directory?
It is a searchable index of 3,385 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.
Where does drug approval data come from?
Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.
How do I find a drug by brand name?
Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.
Data attribution and licensing: Data sources